Basilea Pharmaceutica Ag Stock Price To Earnings To Growth

BPMUF Stock  USD 52.83  0.00  0.00%   
Basilea Pharmaceutica AG fundamentals help investors to digest information that contributes to Basilea Pharmaceutica's financial success or failures. It also enables traders to predict the movement of Basilea Pink Sheet. The fundamental analysis module provides a way to measure Basilea Pharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Basilea Pharmaceutica pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Basilea Pharmaceutica AG Company Price To Earnings To Growth Analysis

Basilea Pharmaceutica's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Competition

Based on the latest financial disclosure, Basilea Pharmaceutica AG has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.

Basilea Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Basilea Pharmaceutica's direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Basilea Pharmaceutica could also be used in its relative valuation, which is a method of valuing Basilea Pharmaceutica by comparing valuation metrics of similar companies.
Basilea Pharmaceutica is currently under evaluation in price to earnings to growth category among its peers.

Basilea Fundamentals

About Basilea Pharmaceutica Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Basilea Pharmaceutica AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Basilea Pharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Basilea Pharmaceutica AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Basilea Pink Sheet

Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.